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Background: Cholesteryl pullulan (CHP) is a novel antigen delivery system for cancer vaccines. This study evaluated
the safety, immune responses and clinical outcomes of patients who received the CHP-NY-ESO-1 complex vaccine,
Drug code: IMF-001.
Methods: Patients with advanced/metastatic esophageal cancer were enrolled and subcutaneously vaccinated with
either 100 μg or 200 μg of NY-ESO-1 protein complexed with CHP. The primary endpoints were safety and humoral
immune responses, and the secondary endpoint was clinical efficacy.
Results: A total of 25 patients were enrolled. Thirteen and twelve patients were repeatedly vaccinated with 100 μg
or 200 μg of CHP-NY-ESO-1 with a median of 8 or 9.5 doses, respectively. No serious adverse events related to the
vaccine were observed. Three out of 13 patients in the 100-μg cohort and 7 out of 12 patients in the 200-μg cohort
were positive for anti-NY-ESO-1 antibodies at baseline. In the 100-μg cohort, an antibody response was observed in 5
out of 10 pre-antibody-negatives patients, and the antibody levels were augmented in 2 pre-antibody-positive patients
after vaccination. In the 200-μg cohort, all 5 pre-antibody-negative patients became seropositive, and the antibody
level was amplified in all 7 pre-antibody-positive patients. No tumor shrinkage was observed. The patients who
received 200 μg of CHP-NY-ESO-1 survived longer than patients receiving 100 μg of CHP-NY-ESO-1, even those who
exhibited unresponsiveness to previous therapies or had higher tumor burdens.
Conclusions: The safety and immunogenicity of CHP-NY-ESO-1 vaccine were confirmed. The 200 μg dose
more efficiently induced immune responses and suggested better survival benefits. (Clinical trial registration
number NCT01003808).
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Complexes of cholesteryl pullulan (CHP) nano-particles
that contain a tumor antigen are a new type of cancer
vaccine with a novel antigen delivery system that presents
multiple epitope peptides to both the MHC class I and class
II pathways [1-4]. We have been developing CHP-protein
human cancer vaccines that efficiently induce immune
responses against multiple T cell epitopes for various
HLA types. Previous clinical studies using CHP-HER2
and CHP-NY-ESO-1 vaccines showed that these vac-
cines could be administered repeatedly without serious
adverse effects, and both vaccines induced antigen-specific
CD4+ and CD8+ T cell immunity as well as humoral
immunity [5-7].
Because the NY-ESO-1 antigen is a cancer-testis antigen
that is exclusively expressed in the tumor tissue, aside from
expression in the normal testis and placenta, this antigen is
considered an ideal target for cancer immunotherapy [8,9].
The appropriate dose for NY-ESO-1 protein vaccine has
not been determined, although doses up to 100 μg have
been examined, in which a higher dose was more immuno-
genic compared to lower doses of 10 μg and 30 μg [10].
We conducted a dose-escalating trial with CHP-NY-
ESO-1 vaccine doses of 100 μg and 200 μg for esophageal
cancer patients who were resistant to standard therapies.
We evaluated the safety and immune responses to the
NY-ESO-1 antigen over the vaccination period, and ex-
plored the clinical impact on esophageal cancer patients
with a poor prognosis.
In this study, we analyzed IgG antibody responses as
antigen-specific immune responses. Although T cells that
are induced by a cancer vaccine should be evaluated as
an immune-monitoring marker, T cells can be difficult
to detect directly and quantitatively assess, whereas
IgG titers measured by ELISA could act as a suitable
immune-monitoring marker. Analyzing antibody responses
induced by CHP-NY-ESO-1 vaccine, the 200 μg-dose more
efficiently induced immune responses and suggested better
survival benefits.
Materials and methods
Preparation of CHP-NY-ESO-1 complex vaccine
CHP-NY-ESO-1 complex vaccine (Drug code: IMF-001)
was provided by ImmunoFrontier, Inc. (Tokyo, Japan).
All processes were performed following current Good
Manufacturing Practices (cGMP) conditions. The toxicity
of the drug products was assessed using animal models,
and stability was monitored during the clinical trial using
representative samples of the investigational drug product.
Study design
This study was a phase 1, open-label, multi-institutional,
dose-escalating clinical trial of the CHP-NY-ESO-1 com-
plex vaccine administered subcutaneously to patientswith unresectable, advanced, or refractory esophageal
tumors that expressed the NY-ESO-1 antigen. The primary
objective was to determine the maximum tolerated dose
(MTD) and the biological recommended dose, and the
secondary objective was to assess clinical efficacy.
Patients were eligible for entry, if they had a perform-
ance status of 0, 1, or 2, were at least 20 years old, had a
life expectancy of 4 months or more, and did not have
impaired organ function. Patients were ineligible if they
were positive for HIV antibody, had multiple cancers,
autoimmune disease, serious allergy history, or active
brain metastasis, or received previous chemotherapy,
systemic steroid or immunosuppressive therapy within
less than 4 weeks.
The patients were divided into the following two cohorts
of 10 patients each: Cohort 1, 100 μg of the NY-ESO-1
protein every two weeks, and Cohort 2, 200 μg of the
NY-ESO-1 protein every two weeks. When a patient
withdrew from the trial within three vaccinations, they
were replaced with an additional patient.
Clinical responses were assessed according to the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST ver1.1)
[11] and its modified version. The modified version is
based on immune-related Response Criteria (ir-RC) [12]
and includes the following: Tumor responses were assessed
every 6 weeks. Even if disease progression was observed
within the first 12 weeks, PD (progressive disease) was
not judged. When disease progression was observed after
18 weeks, PD was determined.
Each patient received 6 administrations. However, the
treatment could be continued beyond this period if the
patient wished to maintain treatment and met the fol-
lowing criteria: 1) no evidence of tumor progression or
worsening of performance status (PS), and 2) an anti-
NY-ESO-1 antibody response was confirmed. Safety was
evaluated according to the National Cancer Institute
Common Terminology Criteria for Adverse Events ver.3.0
(NCI-CTCAE ver.3.0) [13]. All the safety information was
collected and evaluated, and dose escalation was judged
by the Independent Data and Safety Committee.
The study was performed in accordance with the
current version of the Declaration of Helsinki and Good
Clinical Practice. Written informed consent was obtained
from all patients participating in this study. The protocol
was approved by the institutional review board at each
site. The clinical trial was sponsored by ImmunoFrontier,
Inc. (Tokyo, Japan), and registered as ID: NCT01003808
of ClinicalTrials.Gov.
Expression of NY-ESO-1 antigen
NY-ESO-1 expression was assessed by immunohistochem-
istry with the monoclonal antibody, E978 (Sigma-Aldrich,
Saint Louis, MO), [9] or quantitative RealTime-PCR
(qRT-PCR) using specific primers [14].
Table 1 Patients demographics
100 μg 200 μg
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To analyze antigen-specific antibody responses, sera were
collected at baseline and two weeks after each vaccination.
All sera were stored at −80°C until analysis.
Antibody responses to NY-ESO-1 antigen
NY-ESO-1-specific antibodies in the sera were measured
by ELISA as described previously [15]. Briefly, recombinant
NY-ESO-1 proteins (His-tag and GST-tag) and NY-ESO-1
peptides were absorbed onto immunoplates (442404; Nunc,
Roskilde, Denmark) at a concentration of 10 ng/50 μL/well
at 4°C. The collected serum samples were diluted from
1:400 to 1:102,400. After washing and blocking the plate,
the sera were added and incubated for 10 h. After washing,
goat anti-human IgG (H + L chain) (MBL, Nagoya, Japan)
conjugated with peroxidase (The Binding Site, San Diego,
CA) was added. After adding the TMB substrate (Pierce,
Rockford, IL), the plate was read using a Microplate Reader
(model 550; Bio-Rad, Hercules, CA).
Serum samples for 80 healthy volunteers were evaluated
to determine a cut-off level for the anti-NY-ESO-1 antibody
based on the optical density (OD)450–550 absorption value.
The cut-off level of anti-NY-ESO-1 IgG was 0.182. A
sample was considered to be positive for anti-NY-ESO-1
antibodies if the optical density (OD)450–550 absorption
value in the ELISA was at the cut-off level or higher at
a serum dilution of 1:400. The immune responses of
patients with pre-existing anti-NY-ESO-1 antibodies
were judged as augmentation if the serum diluted 4-fold
or more remained positive.
Statistical analysis
Rates of the immune responses between the patients in
Cohort 1 and Cohort 2 were compared by Fisher’s exact
test, and the survival curve was estimated using the
Kaplan–Meier method and compared by the log-rank test.
In order to adjust the confounding factors, Cox propor-
tional hazards model was applied. All analyses were done
using SAS 9.2 (SAS Institute Inc., Cary, NC).
Results and discussion
Patient characteristics and clinical safety
A total of 25 patients were enrolled in the clinical trial.
All patients had unresectable, advanced, or refractory
esophageal cancers. The tumor cells in all of these patients
were NY-ESO-1-positive, in which the positivity was
determined by immunohistochemistry and qRT-PCR
for 24 patients and one patient, respectively. All patients
received standard chemotherapy and/or other cancer
therapies including radiotherapy and surgery, which were
ultimately ineffective (Table 1).
Cohort 1 consisted of 13 patients who were given 100 μg
of the vaccine; Cohort 2 consisted of 12 patients who were
given 200 μg of the vaccine. The patients in Cohort 1 andCohort 2 received 2 to 27 vaccinations with a median of 8
doses and 3 to 21 vaccinations with a median of 9.5 doses,
respectively (Table 1). No dose-limiting toxicity (DLT) was
observed. All the patients except one developed transient,
grade 1 skin reactions at the injection sites. Other adverse
events included swallowing disturbance (n = 8), diarrhea
(n = 3), and fever (n = 2), in which events of grade 3 or 4
were included. These events were considered unrelated to
the CHP-NY-ESO-1 vaccination. Based on the laboratory
data, decreased lymphocyte counts were observed (n = 10),
which were all grade 3. These patients had lymphopenia at
baseline, probably due to the previous chemotherapies.
During the course of the vaccinations, they developed grade
3 lymphopenia, which were shifted from the other grade
of the pre-vaccine lymphopenia. Other changes included
decreased Na levels (n = 4), decreased hemoglobin levels
(n = 3), elevated transaminase levels (n = 2) and elevated
uric acid (n = 2) (Table 2). These adverse events were
changed from the decreased or elevated levels at baseline.
They did not affect the vaccine continuation. Therefore,
the changes were considered not related or unlikely related
to the vaccination.
Immune responses to NY-ESO-1 protein
As shown Table 3, 3 out of the 13 patients, and 7 out of
12 patients had pre-existing antibodies to NY-ESO-1,
while the remaining 10 and 5 patients did not have this
reactivity in Cohort 1 and Cohort 2, respectively.
To evaluate the antibody responses after vaccination,
serum samples collected at the serial vaccinations were
analyzed using an antigen-specific IgG ELISA. In three
patients of 100–02, 100–3 and 200–7 who were vacci-
nated three times, the serum samples from 1st and 2nd
Table 2 Adverse events during CHP-NY-ESO-1 vaccinations
100 μg(n = 13) 200 μg(n = 12) Total
Adverse event Grade Grade
1 2 3 4 5 Subtotal 1 2 3 4 5 Subtotal
Skin reaction 12 0 0 0 0 12 12 0 0 0 0 12 24
Swallowing disturbance 0 0 3 0 0 3 0 0 4 1 0 5 8
Diarrhea 0 0 2 0 0 2 1 0 0 0 0 1 3
Fever 2 0 0 0 0 2 0 0 0 0 0 0 2
Decreased lymphocytes count 0 0 7 0 0 7 0 0 3 0 0 3 10
Decreased Na level 0 0 2 0 0 2 0 0 2 0 0 2 4
Decreased Hb level 0 0 3 0 0 3 0 0 0 0 0 0 3
Elevated ALT/AST level 0 0 2 0 0 2 0 0 0 0 0 0 2
Elevated uric acid level 0 0 1 1 0 2 0 0 0 0 0 0 2
NOTE: Events occurring more than once are listed. Events of disease progression are not listed.
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antibody-negative patients, 5 became seropositive. Two out
of 3 pre-antibody-positive patients had augmented antibody
responses. In total, 7 of 13 (53.8%) patients exhibited
immune responses. Five pre-antibody-negative and 7 pre-
antibody-positive patients in Cohort 2 became positive or
were augmented, yielding 12 out of 12 or 100% responsive-
ness. The 200-μg dose was more immunogenic than the
100-μg dose (p = 0.015, Fisher’s exact test). In Cohort 1, im-
mune reactions were observed after a median of 2 cycles,
with a range of 1 to 4 vaccine cycles. In Cohort 2, the im-
mune responses were also evident after a median of 2 cycles
with a range of 1 to 5 cycles (Table 3). The chronological
appearance of the immune responses and antibody titers








100-01 9 negative responded(4)
100-02 3 negative no response**
100-03 3 negative no response**
100-04 7 negative no response
100-05 2 negative no response
100-06 16 positive (x6,400) responded(1)
100-07 9 positive (x25,600) no response
100-08 10 negative responded(1)
100-09 5 negative no response
100-10 27 positive (x400) responded(3)
100-11 8 negative responded(2)
100-12 8 negative responded(2)
100-13 26 negative responded(2)
antibody response rate 53.8%***
*vaccine cycles with which antibody responses appeared. **antibody responses assmore quickly and at a higher titer in patients in Cohort 2
(200 μg) than those in Cohort 1(100 μg). In addition to
His-tag NY-ESO-1 protein, we tested serum reactivities
to GST-tag NY-ESO-1 protein and NY-ESO-1 peptides.
We confirmed specific reactions to NY-ESO-1 antigen
in these sera.
Clinical responses and long-term follow-up
There were no cases of tumor shrinkage with partial
response (PR) or complete response (CR) in any of the 25
patients. At the assessment that occurred every 6 weeks
after vaccination, stable disease (SD) was observed in 3
patients in Cohort 1 and 6 patients in Cohort 2 (Table 4).
There was no discordance in the evaluations between








200-01 15 negative responded(2)
200-02 9 negative responded(2)
200-03 8 positive (x1,600) responded(5)
200-04 21 negative responded(2)
200-05 3 negative responded(2)
200-06 10 positive (x400) responded(1)
200-07 3 positive (x25,600) responded(2)**
200-08 11 positive (x400) responded(1)
200-09 18 positive (x400) responded(3)
200-10 11 positive (x400) responded(2)
200-11 3 positive (x400) responded(2)
200-12 9 negative responded(1)
100%***
ayed after two vaccinations.***p = 0.015(Fisher’s exact test).
























































Figure 1 Antibody responses to recombinant NY-ESO-1 protein as determined by ELISA. Sera from 13 patients in Cohort 1 (100-μg dose)
and 12 patients in Cohort 2 (200-μg dose) were collected at each vaccination, and serially diluted by 400, 1,600, 6,400, 25,600 and 102,400.
Reciprocal titers were determined based on the maximally diluted sera, which showed a higher OD (optical density of 450–500) value than the
cut-off level for NY-ESO-1 antibody positivity.
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on average, with a median of 6 weeks and range of 4 to
52 weeks. In Cohort 1 (n = 13), patients who were vacci-
nated with 100 μg of CHP-NY-ESO-1 survived without
disease progression for 11 weeks on average, with a me-
dian of 6 weeks and range of 4 to 52 weeks. In Cohort 2
(n = 12) in which patients received the 200-μg dose,
the patients were progression-free for 10 weeks on average,
with a median of 8.5 weeks and range of 6 to 18 weeks
(Table 4). There was no difference between the two cohorts
(p = 0.748, Figure 2-A).
The overall survival time was 33 weeks on average,
with a median of 31 weeks and range of 4 to 72 weeks.
In Cohort 1 (n = 13), the patients survived for 25 weeks
on average, with a median of 23 weeks and range of 4 to
60 weeks. In Cohort 2 (n = 12), they survived for 41 weeks
on average, with a median of 41 weeks and range of 8 to
72 weeks (Table 4). The patients vaccinated with 200 μg of
CHP-NY-ESO-1 had statistically longer survival than those
who received the 100-μg dose (p = 0.050, Figure 2-B). Each
cohort included three patients who were vaccinated three
times or less because of early disease progression, and
were withdrawn from this study, respectively. Having
excluded those 6 patients, the patients vaccinated with
200 μg-vaccine still had longer survival than those with
100 μg-vaccinations (data not shown).When the survival of patients who had responded
to previous therapies (n = 12) was compared to non-
responders (n = 13), the responders lived longer than the
non-responders after vaccination (p = 0.005, Figure 2-C).
The patients who never responded to previous therap-
ies and received the 200-μg dose (n = 6) significantly
lived longer than those who received the 100-μg dose
(n = 7) (p = 0.029, Figure 2-D).
When the survival of patients who had tumors with a
maximal diameter of 30 mm or less, including non-
measurable lesions (n = 13) was compared with those with
diameters more than 30 mm (n = 12), the patients with
higher tumor burdens had shorter life spans (p = 0.021,
Figure 2-E). Among patients with higher tumor burdens,
patients who were vaccinated with the 200-μg dose (n = 4)
lived longer than those who received the 100-μg dose
(n = 8), (p = 0.037, Figure 2-F).
Using Cox proportional hazards models, the vaccine dose
and the responsiveness to previous therapy were independ-
ent factors that influenced the overall survival, which showed
p = 0.011 with HR 3.595 (95%CI 1.335-9.678) and p = 0.002
with HR 0.194 (95%CI 0.068-0.553), respectively. Also, the
vaccine dose and the tumors sizes including non-measurable
disease independently affected the overall survival, showing
p = 0.040 with HR 2.630 (95%CI 1.045-6.614) and p = 0.020
with HR 0.322 (95%CI 0.124-0.833), respectively.
Table 4 Baseline clinical profiles and responses after CHP-NY-ESO-1 vaccinations
100 μg 200 μg
























100-01 PR (4) NA PD 6 31 200-01 PR (29) 24 SD 17 70
100-02 SD 53 NE 4 6 200-02 NE 25 SD 18 33
100-03 NE 144 NE 4 6 200-03 PR (32) 55 PD 6 37
100-04 PD 182 PD 5 17 200-04 PR (30) NA PD 6 50
100-05 CR (38) 101 NE 4 4 200-05 PR (32) NA PD 6 72
100-06 SD 69 PD 6 31 200-06 NE 32 SD 18 54
100-07 CR (15) 78 PD 6 29 200-07 NE 205 NE 6 8
100-08 NE 39 SD 18 23 200-08 PR (12) 16 SD 11 33
100-09 SD 18 PD 6 8 200-09 CR (96) 88 PD 6 45
100-10 CR (24) NA SD 11 60 200-10 SD NA SD 12 48
100-11 SD 31 SD 12 20 200-11 SD NA NE 6 12
100-12 PR (9) NA NE 16 28 200-12 SD NA SD 12 33
100-13 PR (16) NA NE 52 59
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Figure 2 Kaplan-Meier survival curves of patients who were alive after the CHP-NY-ESO-1 vaccinations. A: Progression-free survival (PFS)
of patients assigned to Cohort 1 (100-μg dose, n = 13) or Cohort 2 (200-μg dose, n = 12). The probability of PFS of the patients who received
200 μg of the vaccine and those who received the 100-μg dose were similar (log-rank test, p = 0.748). B: Overall survival (OS) of patients assigned
to Cohort 1 or Cohort 2. The patients who received 200 μg of the vaccine survived longer than those who received the 100-μg dose. (log-rank
test, p = 0.050). C: OS of patients vaccinated with either 100 μg or 200 μg of CHP-NY-ESO-1 compared between patients who responded to
previous therapies and those who never responded. The patients who responded to previous therapies and were vaccinated with CHP-NY-ESO-1
survived longer than non-responders. (log-rank test, p = 0.0050). D: OS of patients vaccinated with 100 μg or 200 μg of CHP-NY-ESO-1 who never
responded to previous therapies. The patients who received 200 μg of the vaccine survived longer than those who received the 100-μg dose
(log-rank test, p = 0.029). E: OS of patients vaccinated with 100 μg or 200 μg of CHP-NY-ESO-1 compared with either baseline tumor burdens
of >30 mm (sum of the tumor diameters) or 30 mm or less including non-measurable lesions. The patients with a tumor burden higher than
30 mm had reduced survival compared to those with smaller burdens (log-rank test, p = 0.021). F: OS of patients who received 100 μg or 200 μg
of CHP-NY-ESO-1 who had baseline tumor burdens greater than 30 mm. The patients who received 200 μg of the vaccine survived longer than
those who received the 100-μg dose (log-rank test, p = 0.037).
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that examined two doses of the CHP-NY-ESO-1 vaccine
in esophageal cancer patients. The primary goals were
to evaluate the vaccine safety and immune responses
to the NY-ESO-1 antigen, and we further explored the
clinical effects on esophageal cancer patients with a
poor prognosis.
CHP consists of a hydrophobic polysaccharide pullulan
containing chemically introduced cholesterol groups, which
spontaneously aggregate to form nano-sized particles
that can contain antigen proteins. Using this system as
a vaccine, tumor antigen proteins delivered to antigen-
presenting cells can stimulate both antigen-specific
CD4+ T cells and CD8+ T cells. In a pre-clinical study,
dendritic cells pulsed with the CHP-NY-ESO-1 com-
plex could induce both NY-ESO-1-specific CD4+ and
CD8+ T cells [4]. Previous clinical studies using CHP-
HER2 and CHP-NY-ESO-1 vaccines have shown thatthese vaccines can induce antigen-specific CD4+ and
CD8+ T cell immunity in cancer patients [5-7].
In the current study, we found that CHP-NY-ESO-1
was clinically safe and that the immune responses to the
NY-ESO-1 antigen, which were evaluated based on IgG
antibody titers, showed a dose-dependent effect between
the 100-μg dose and 200-μg. Furthermore, the survival
rates of patients who were vaccinated with the 200-μg
dose were superior to those who received the 100-μg
dose. The patients had recurrent or metastatic esopha-
geal tumors that exhibited clinical resistance to chemothe-
rapy or radiotherapy. The first 13 patients were enrolled
to Cohort 1, and the next 12 patients were included in
Cohort 2. As the clinical backgrounds of the two cohorts
were similar, it was reasonable to make a comparative
consideration.
As the previous NY-ESO-1 protein vaccine trials have
demonstrated, the toxicity of the CHP-vaccine was very
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were likely related to the progression of esophageal cancer.
The other grade 3 events included diarrhea, which was not
related to the vaccine. The only related events were grade 1
skin reactions at the injection sites.
Previous vaccine trials have used recombinant full-length
NY-ESO-1 protein with various adjuvants. Melanoma
patients were divided into three cohorts that were vacci-
nated with 10 μg, 30 μg or 100 μg of the NY-ESO-1 protein
in combination with the saponin adjuvant ISCOMATRIX
[10]. The 100-μg dose of NY-ESO-1 induced more immune
responses than the other two doses. The responses were
evaluated based on IgG antibody titers and delayed-type
hypersensitivity (DTH) of skin reactions. In the CHP sys-
tem, a single 100-μg dose of CHP-NY-ESO-1 was exam-
ined with or without the adjuvant OK-432 [6,7,16]. These
reports suggested that the 100-μg dose of CHP-NY-ESO-1
is sufficient to induce immune responses. The current trial
was designed to determine whether the NY-ESO-1 protein
vaccine has potential dose-dependent effects on immuno-
genicity in patients with homogeneous backgrounds. By
assessing humoral immune responses in the cohorts that
received 100 μg and 200 μg of the vaccine, the responses
appeared in the early phases. We initially intended to
analyze antibodies using samples from patients who were
vaccinated for at least 4 cycles, as we thought it could take
at least 4 cycles to detect immune responses. In the overall
data acquisition, samples from all 25 patients were ana-
lyzed, which included sera from at least two vaccinations.
In conclusion, we found that the 200-μg dose was more
efficient than the 100-μg dose.
The other reports included vaccine studies using recom-
binant NY-ESO-1 protein in combination with Imiquimod
and CpG [17,18]. In these studies, the NY-ESO-1 protein
was given at doses of 100 μg, and 100 μg or 400 μg,
respectively. Based on the patients’ sera, the 400-μg dose
might have induced more antibody responses than the
100-μg dose, but this was not statistically analyzed. Com-
bined with these reports, the NY-ESO-1 protein might be
immunogenic at increasing doses of 10 μg, 30 μg, 100 μg
and 200 μg. Since dose-limited toxicity (DLT) was not ob-
served at the higher dose of 200 μg in this study, additional
dose increments might be acceptable to determine whether
higher doses can induce stronger immune responses.
In this study, we explored a long-term clinical outcome
of the NY-ESO-1 protein vaccine. This study was not
initially designed to detect a statistical significance of
the clinical effect between the 2 cohorts. Instead, we
made a comparison to find out if there might include
a positive signal for further clinical trials of this vac-
cine. The NY-ESO-1 protein vaccine with the adjuvant
ISCOMATRIX suggested that melanoma patients who
were vaccinated after standard therapy tended to have
fewer relapses [10], which were not statistically analyzed.The other studies reported that vaccinations with NY-ESO-
1-expressing poxvirus vectors and NY-ESO-1 overlapping
peptides both prolonged progression-free survivals in ovar-
ian cancer patients who did not have measurable disease
after standard therapy [19,20]. In this study, most of the pa-
tients developed disease-progression in 6 months, and there
was no difference between the patients vaccinated with
100 μg and 200 μg of the CHP-NY-ESO-1, as the previous
studies demonstrated that disease-progression occurs in the
early phase of vaccinations [12,21].
In contrast, we found that dose-dependent effects of
the CHP-NY-ESO-1 vaccine on overall survival of patients
with advanced/metastatic esophageal cancer. Analyzing
other clinical categories, both the baseline tumor sizes and
the tumor responsiveness to previous therapies were signifi-
cant factors influencing the overall survival. Using Cox pro-
portional hazards models, it was indicated that the tumor
sizes and the vaccine doses independently influenced the
survival. In the same way, the responsiveness to previous
therapies and the vaccine doses independently affected the
survival. Therefore, it is suggested that the higher dose of
CHP-NY-ESO-1 vaccine played a role in prolongation of
the overall survival in the esophageal cancer patients.
In addition, the higher-dose of the vaccine provided sig-
nificant survival benefit in patients who never responded to
the previous therapies or had larger tumor burdens than the
lower dose vaccinations. It is difficult to discuss why the pa-
tients with a poorer prognosis were more benefited from
the 200-μg dose of the vaccine than 100-μg. It might be
speculated that the dose-dependency clinical benefits were
more often observable in patients with a poorer prognosis,
because they might have needed more immune responses in
order to survive longer by preventing disease deterioration.
In the previous CHP-NY-ESO-1 vaccine study, which was
a phase 1 study that enrolled various types of NY-ESO-1-
expressing cancer patients, tumor regression was observed
in two out of four esophageal cancer patients [6]. However,
tumor shrinkage is rarely observed in cancer vaccine the-
rapies, although some disease stabilization is seen. This
study shows that clinical benefits, such as long-term survival,
can be detected if a clinical trial is designed in a comparative
way. The results were not compared to unvaccinated con-
trols, and it is not possible to directly determine the effects
of the vaccine, but is possible to reasonably interpret the
effects of immune response on the clinical outcomes.
Conclusions
The safety and immunogenicity of the CHP-NY-ESO-1
vaccine were confirmed in the patients with antigen-
expressing esophageal cancer. The 200-μg dose efficiently
induced antigen-specific immune responses and suggested
better survival benefits, even for patients with a poorer
prognosis. In future clinical trials, 200 μg will be the
recommended dose.
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